Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.57 |
| ▸ | MEN1 | O00255 | 3/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.56 |
| ▸ | NAMPT | P43490 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2388387 | 0.96 | MAPT (0.62) | MAPTALDH1A1LMNASMN1; SMN2KMT2A | |
| SCHEMBL64850 | 0.91 | SMN1; SMN2 (0.57) | MAPTALDH1A1LMNASMN1; SMN2KMT2A | |
| SCHEMBL24891935 | 0.87 | MAPT (0.62) | MAPTALDH1A1LMNASMN1; SMN2KMT2A | |
| SCHEMBL11889811 | 0.87 | MAPT (0.62) | MAPTALDH1A1LMNASMN1; SMN2KMT2A | |
| SCHEMBL3485718 | 0.85 | GPR119 (0.78) | MAPTALDH1A1LMNASMN1; SMN2KMT2A | |
| SCHEMBL5573222 | 0.85 | MAPT (0.76) | MAPTALDH1A1LMNASMN1; SMN2KMT2A | |
| SCHEMBL3107842 | 0.84 | GPR119 (0.64) | GPR119PKM | |
| SCHEMBL34470079 | 0.84 | MAPT (0.50) | MAPTALDH1A1LMNASMN1; SMN2KMT2A | |
| SCHEMBL1218834 | 0.84 | SMN1; SMN2 (0.64) | MAPTALDH1A1LMNASMN1; SMN2KMT2A | |
| SCHEMBL5542227 | 0.84 | GPR119 (0.65) | MAPTALDH1A1LMNASMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6884774-B2 | Cyclic hexapeptide derivatives | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2005-04-26 | — | — | US | disclosed |
| EP-1259535-B1 | CYCLIC HEXAPEPTIDE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO (JP) | 2005-04-13 | — | — | EP | disclosed |
| US-20030083238-A1 | Cyclic hexapeptide derivatives | ASTELLAS PHARMA INC. (JP) | 2003-05-01 | — | — | US | disclosed |
| EP-1259535-A1 | CYCLIC HEXAPEPTIDE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-11-27 | — | — | EP | disclosed |
| WO-2001060846-A1 | CYCLIC HEXAPEPTIDE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030083238-A1 | Cyclic hexapeptide derivatives | NGLY1, ALG1, CHIT1 | MAPT 3424/4885ALDH1A1 4718/4885LMNA 2471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.